RKRajesh Kumar

Rajesh Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rajesh Kumar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Updated Review of Customized Onboarding Strategies for Faculty in Competency-based Medical Education: Emerging Principles and Challenges

    by Prashant Kumar Singh, Shruti Singh, Veena Kumari Singh, Rajesh Kumar Meena

    Competency-based medical education (CBME) marks a paradigm shift in medical training by prioritizing outcomes over time-based progression and focusing on clearly defined competencies aligned with societal needs. Faculty serve as critical agents of this transformation, but the success of CBME implementation depends significantly on effective and sustained faculty onboarding. This narrative review examines customized onboarding strategies in CBME and explores emerging principles and challenges. A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and Google Scholar using keywords such as CBME, faculty development, onboarding, and competency-based assessment. Articles published between 2019 and 2025 were included based on relevance, empirical content, and English language. Data from selected studies were thematically analyzed and validated through expert consultation. Findings highlight persistent challenges in onboarding, such as resistance to change, time constraints, inadequate institutional support, and variable CBME familiarity. The review outlines a phased onboarding model—from preonboarding to continuous support—emphasizing the use of online learning platforms, simulation tools, and peer mentoring to improve faculty readiness. Success metrics include faculty engagement, learner performance, and longitudinal faculty development. While evidence supports CBME’s effectiveness in improving learner outcomes, further empirical validation is warranted to evaluate the impact of tailored onboarding on faculty performance. The review underscores the need for sustainable, context-sensitive, and tech-enabled onboarding frameworks to foster institutional capacity for CBME.

  • Navigating retatrutide safety: comprehensive insights from systematic review and meta-analysis

    by Vikas Maharshi, Shruti Singh, Pramod Kumar Manjhi, Sunil Kumar Singh, Alok Kumar, Rajesh Kumar

    Retatrutide, a triple agonist (GIP, GLP-1, glucagon receptors), has shown promise in glycaemic control and weight loss, but its safety profile has not been studied in earlier studies. This study aims to systematically evaluate the safety profile of retatrutide by analyzing the incidence and risk of treatment-emergent adverse events. Through a comprehensive review of existing literature, the study seeks to quantify the relative risk of adverse effects, to inform clinical decision-making and future research directions. A systematic literature review following PRISMA 2020 guidelines was conducted across PubMed, Google Scholar, and Science Direct, focusing on studies investigating retatrutide's safety, and we excluded other studies (systematic reviews, narrative reviews, meta-analyses, etc.). Adverse event data, including treatment-emergent adverse events, were pooled and analysed for frequency and risk estimation. A total of 1,331 studies were initially identified, and after applying stringent inclusion and exclusion criteria, four studies were included in this Meta-analysis. We found that retatrutide significantly increased the incidence of adverse events compared to placebo (RR 1.87; 1.25, 2.80; p=0.003), with gastrointestinal disturbances (Nausea, decreased appetite, vomiting, constipation, etc.) being the most common. No significant difference in serious adverse events was observed (RR 0.81; 0.36, 1.83; p=0.61). Adverse events of special interest, such as hypersensitivity and pancreatitis, were notably higher in the retatrutide group (RR 2.94; 1.85, 4.69; p<0.00001). Retatrutide is effective for glycemic control and weight loss, but it increases the incidence of treatment-emergent adverse events, especially gastrointestinal issues, hypersensitivity, and pancreatitis. While serious adverse events were not significantly higher, careful patient selection, dose titration, and monitoring are crucial for patients with GI disorders, hypersensitivity, hepatic disease, cardiac disease etc. Clinicians should assess risks, particularly in vulnerable patients. Future research should explore the long-term safety of retatrutide and compare it with other therapies to refine treatment strategies and improve clinical decision-making.

  • Open Access

    Vitamin D supplementation trials: Navigating the maze of unpredictable results

    by Shruti Singh, Rajesh Kumar Meena, Vikas Maharshi, Nishi Sinha, Neha Agarwal, Shuvasree Payra, Divya Harsha

    Vitamin D supplementation studies in various pleiotropic outcomes often yield conflicting results. This complexity arises from various factors, including individual differences (baseline Vitamin D levels, genetics, ethnicity, age, and gender). This review aims to clarify the complexities in Vitamin D supplementation research by examining various influencing factors, ultimately providing a comprehensive understanding to guide future studies and offer more accurate insights into the health impacts of Vitamin D supplementation. For this review, we searched PubMed, Google Scholar, and ScienceDirect, analyzing observational studies, meta-analyses, and randomized controlled trials to identify key factors influencing the efficacy of Vitamin D supplementation. By synthesizing findings from diverse research, we aimed to illuminate the nuances shaping the outcomes of these trials. In conclusion, the review suggests that several demographic and biological factors such as baseline 25(OH)D levels, age, ethnicity, genetics, body mass index, diet, sun exposure, medications, comorbid conditions, socioeconomic status, and self-supplementation all play significant roles in the outcomes of Vitamin D supplementation trials. In addition, the dose and duration of therapy, choice of daily versus bolus dosing, route of administration, and the role of free and bound forms of Vitamin D contribute to the complexity of trial results. Vitamin D’s pleiotropic effects extend beyond calcium regulation, impacting various health aspects. Inadequate blood levels can confound trial outcomes, emphasizing the importance of reaching appropriate 25(OH)D thresholds. Study design, sample size, bias minimization, and methodology are critical in influencing trial outcomes and designing studies that account for baseline levels and compliance is crucial for meaningful and accurate results. Standardized assays and internationally agreed-upon cutoff levels are essential to mitigate variability in 25(OH)D measurements and improve result reliability.


  • Open Access

    From Diversity to Standardization: Unveiling Key Parameters in Chick Ileum Bioassays for Enhanced Pharmacology Education and Research

    by Shruti Singh, Rajesh Kumar, Sunil Kumar Singh, Vikas Maharshi

    Background: As traditional laboratory animal use faces ethical and logistical constraints, the chick ileum has been experimented with as an alternate tissue for bioassays, which is crucial for drug discovery and pharmacology education. However, the absence of uniform bioassay protocols for chick ileum presents a significant challenge, impacting the accuracy and reliability of results in pharmacological studies. Objectives: The objective of this review was to compile existing data on chick ileum bioassays from published sources, aiming to enhance future experiments and contribute to the establishment of standardized methods for conducting these bioassays. Methodology: We conducted a systematic literature review, utilizing keywords like “Chick ileum,” “Bioassay,” “Acetylcholine,” and “Histamine” across databases such as PubMed, Google Scholar, and ScienceDirect. The study selection adhered to specified inclusion and exclusion criteria, focusing on chick ileum research. Data extraction and subsequent analysis were performed to retrieve data for the experiment. Results: Eleven articles were selected after applying strict inclusion criteria. Studies ranged from 1967 to 2019, with diverse physiological salt solutions and varied responses to essential chemicals like acetylcholine and histamine. Assay methods varied, but three-point assays were common. Commonly employed tissue lengths and temperatures were identified, and additional factors like organ bath volume and aeration were crucial for consistent results. Conclusion: The review highlights the feasibility and ethical advantages of using chick ileum for bioassays. Despite challenges like variable tissue responses and methodological diversity, the review suggests these can be navigated with careful optimization, making chick ileum a valuable model for pharmacological research and education.

  • Open Access

    Harnessing Artificial Intelligence for Advancing Medical Manuscript Composition: Applications and Ethical Considerations

    by Shruti Singh, Rajesh Kumar, Vikas Maharshi, Prashant K. Singh, Veena Kumari, Meenakshi Tiwari, Divya Harsha, Veena Kumari Iv

    Scientific medical manuscripts are fundamental to advancing research and enhancing patient care. With the emergence of artificial intelligence (AI), the process of composing such manuscripts has witnessed profound transformations. This review delves into the multifaceted role of AI in medical manuscript composition, analyzing its applications, benefits, drawbacks, and ethical implications. Employing a comprehensive narrative review methodology, we explored databases such as PubMed, Google Scholar, and Science Direct. The review charts the evolution of AI in medical writing, from basic word processing to sophisticated neural network-based models like GPT-3 and GPT-4. Various AI-powered tools such as ChatGPT, Google Bard, Elicit, and Consensus AI are examined in terms of their functionalities and contributions to research and medical writing. While AI technologies offer notable advantages in automating content creation and boosting research productivity, concerns persist regarding overreliance, potential homogenization of writing styles, and ethical considerations such as originality and authorship. Because of this concern, some companies are restricting the use of AI in peer review processes, medical examinations, etc. It is crucial to strike a balance in integrating AI tools, ensuring human oversight, conducting thorough algorithm audits, addressing financial implications, and upholding academic integrity. The review underscores the transformative potential of AI in medical manuscript composition while emphasizing the ongoing significance of human expertise, creativity, and ethical responsibility in scientific communication. Recommendations are provided for the effective integration of AI tools into medical writing processes, emphasizing collaborative efforts between AI developers, researchers, and journal editors to navigate ethical dilemmas and maximize the benefits of AI-driven advancements in scientific publishing.


  • Risk of Congenital Anomalies with Dolutegravir-Based Anti-retroviral Regimens: A Systematic Review and Meta-analysis

    by Shuvasree Payra, Divya Harsha, Keshav Kumar, Pramod Kumar Manjhi, Shruti Singh, Rajesh Kumar, Sunil Kumar Singh, Alok Kumar, Vikas Maharshi

    Background and Objectives Dolutegravir has been used as a first-line anti-human immunodeficiency virus drug because of its better efficacy compared with other counterpart medicines. However, making a unanimous decision on its use during pregnancy has become difficult for stakeholders following congenital anomalies reported with its use. The objective of this systematic review and meta-analysis was to study the risk of congenital anomalies in newborns exposed to dolutegravir-based-regimens compared with those exposed to non-dolutegravir-based regimens during the antenatal period. Methods An extensive literature search was performed in MEDLINE (through PubMed), EMBASE, Cochrane Database of Systematic Reviews, Google Scholar, and ClinicalTrials.gov until 30 November, 2023. Studies reporting data on congenital anomalies following antenatal use of dolutegravir were included. Risk of bias for randomized controlled trials, non-randomized controlled trials, and observational studies was assessed using RoB2, ROBINS-I, and ROBINS-E tools, respectively. A meta-analysis was performed in ‘RevMan 5.4.1’ using a random-effects model. Heterogeneity was assessed by the ‘Q’ statistic and I2 value. A sensitivity analysis was performed for higher heterogeneity/high-risk studies. The study protocol was registered in PROSPERO [CRD42023446374] a priori. Results Of 26 eligible studies, 12 (six randomized controlled trials and six observational studies with a pooled sample of 32,617) were included in a meta-analysis and 14 in a qualitative synthesis only. The meta-analysis does not show a statistically significant difference in the risk of congenital anomalies between newborns exposed antenatally to dolutegravir-based regimen(s) and those exposed to non-dolutegravir-based regimens [risk ratio 1.10; 95% confidence interval 0.79–1.53; p = 0.59]. Heterogeneity was moderate (I2 = 47%). Pooled results for randomized controlled trials and observational studies separately and the sensitivity analysis for heterogeneity provided similar results. Conclusions The risk of congenital anomalies was not significantly different between dolutegravir-based regimens and non-dolutegravir-based-regimens in newborns exposed during their antenatal period.

  • Effect of cannabinoids in mild-to-moderate cases of Crohn’s disease as compared to placebo: a systematic review and meta-analysis of randomised controlled trials

    by Rajesh Kumar, Shruti Singh, Vikas Maharshi

    Introduction: In view of limited treatment options (those too may fail) for Crohn’s disease, cannabinoids have been tried as a therapeutic. However, their efficacy is not unequivocally established. This systematic review and meta-analysis was planned to pool data from randomised controlled trials (RCTs) evaluating effect of cannabinoids in Crohn’s disease with an intention to take this uncertainty away. Content: Following literature search in Medline, EMBASE, Scopus and Google Scholar databases, RCTs assessing the effect of cannabinoids on mild-to-moderate Crohn’s disease in adults were included. Crohns’ disease activity index (CDAI), QoL (Quality of life), number participants achieving full remission and serum CRP at eight weeks of treatment were the outcomes considered for meta-analysis. Quality of studies was assessed using Cochrane’s RoB2 tool. Random effect model was applied for meta-analysis. Heterogeneity was assessed by Cochrane ‘Q’ statistics and I 2 test. Sensitivity analysis was performed to identify the major contributor(s) to heterogeneity and assess robustness of the results. Summary: Risk of bias for the four included studies varied from ‘low’ to ‘some concern’. Overall effect estimate (SMD −0.92; 95 % CI −1.80, −0.03) indicated a statistically significant effect of cannabinoids as compared to control (p<0.05) on CDAI score. Effect of cannabinoids on rest of the outcome parameters was comparable to that of placebo. Magnitude of heterogeneity for different outcome parameters ranged from ‘low’ to ‘substantial’. Outlook: Cannabinoids were superior to placebo for favourably affecting the disease severity in terms of CDAI score. However, no statistically significant difference was found between the two for improving QoL, causing full disease-remission and reducing inflammatory markers. The results must be interpreted with caution in view of relatively high heterogeneity among the studies.


  • HIV cure: Are we going to make history?

    by Shuvasree Payra, Pramod Kumar Manjhi, Shruti Singh, Rajesh Kumar, Sunil Kumar Singh, Alok Kumar, Vikas Maharshi

    Background: At present, combination antiretroviral therapy (cART) is the mainstay for the treatment of people living with HIV/AIDS. cART can suppress the viral load to a minimal level; however, the possibility of the emergence of full‐blown AIDS is always there. In the latter part of the first decade of the 21st century, an HIV‐positive person received stem cell transplantation (SCT) for treatment of his haematological malignancy. The patient was able to achieve remission of the haematological condition as well as of HIV following SCT. Thorough investigations of various samples including blood and biopsy could not detect the virus in the person's body. The person was declared to be the first cured case of HIV.Literature search: Over the next decade, a few more similar cases were observed and have recently been declared cured of the infection. A comprehensive search was performed in PubMed, Cochrane library and Google Scholar. Four such additional cases were found in literature.Description & Discussion: These cases all share a common proposed mechanism for the HIV cure, that is, transplantation of stem cells from donors carrying a homozygous mutation in a gene encoding for CCR5 (receptor utilized by HIV for entry into the host cell), denoted as CCR5△32. This mutation makes the host immune cells devoid of CCR5, causing the host to acquire resistance against HIV. To the best of our knowledge, this is the first review to look at relevant and updated information of all cured cases of HIV as well as the related landmarks in history and discusses the underlying mechanism(s).


  • Top Cited Papers
    Open Access

    Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery

    by Shruti Singh, Rajesh Kumar, Shuvasree Payra, Sunil K. Singh

    Artificial intelligence (AI) has transformed pharmacological research through machine learning, deep learning, and natural language processing. These advancements have greatly influenced drug discovery, development, and precision medicine. AI algorithms analyze vast biomedical data identifying potential drug targets, predicting efficacy, and optimizing lead compounds. AI has diverse applications in pharmacological research, including target identification, drug repurposing, virtual screening, de novo drug design, toxicity prediction, and personalized medicine. AI improves patient selection, trial design, and real-time data analysis in clinical trials, leading to enhanced safety and efficacy outcomes. Post-marketing surveillance utilizes AI-based systems to monitor adverse events, detect drug interactions, and support pharmacovigilance efforts. Machine learning models extract patterns from complex datasets, enabling accurate predictions and informed decision-making, thus accelerating drug discovery. Deep learning, specifically convolutional neural networks (CNN), excels in image analysis, aiding biomarker identification and optimizing drug formulation. Natural language processing facilitates the mining and analysis of scientific literature, unlocking valuable insights and information. However, the adoption of AI in pharmacological research raises ethical considerations. Ensuring data privacy and security, addressing algorithm bias and transparency, obtaining informed consent, and maintaining human oversight in decision-making are crucial ethical concerns. The responsible deployment of AI necessitates robust frameworks and regulations. The future of AI in pharmacological research is promising, with integration with emerging technologies like genomics, proteomics, and metabolomics offering the potential for personalized medicine and targeted therapies. Collaboration among academia, industry, and regulatory bodies is essential for the ethical implementation of AI in drug discovery and development. Continuous research and development in AI techniques and comprehensive training programs will empower scientists and healthcare professionals to fully exploit AI's potential, leading to improved patient outcomes and innovative pharmacological interventions.